Alpha Level

The alpha level, also called the significance level, is the predetermined probability threshold below which the null hypothesis is rejected in a statistical test. Conventionally set at 0.05, it represents the maximum probability of committing a Type I error, which is the error of concluding that an effect exists when it does not.^[1]

The alpha level is one of the most consequential decisions in study design because it determines what counts as sufficient evidence against the null hypothesis. It shapes sample size calculations, influences the interpretation of results, and sets the evidentiary bar for clinical and policy decisions. Regulatory agencies rely on pre specified alpha levels to evaluate whether a drug or device has demonstrated efficacy. Journal editors and peer reviewers expect researchers to state their alpha level in advance and to interpret their results accordingly. The ongoing debate about whether the conventional 0.05 threshold is too lenient has led some researchers and journals to advocate for more stringent thresholds, particularly in fields where false positive findings have proven difficult to replicate.^[2][3]

Before data collection begins, the researcher specifies the alpha level in the study protocol or statistical analysis plan. This value defines the rejection region of the test statistic's sampling distribution. If the p value calculated from the observed data falls below the alpha level, the null hypothesis is rejected, and the result is declared statistically significant.

An alpha of 0.05 sets a 5% Type I error threshold: if the null hypothesis is true (that is, if there is truly no effect) and the test's assumptions hold, the testing procedure will wrongly reject it no more than 5% of the time. The p value is a separate quantity, calculated from the observed data: the probability, assuming the null hypothesis is true, of a test statistic as extreme as or more extreme than the one obtained. Alpha is fixed before the data are seen; the p value is then compared against it. This 5% threshold is a convention rather than a mathematical necessity; it was popularized by Ronald Fisher in the early twentieth century and has persisted largely through disciplinary tradition.^[1]

When a study involves multiple statistical comparisons, the probability of at least one Type I error increases. For example, conducting 20 independent tests at alpha = 0.05 yields an expected one false positive even when all null hypotheses are true. To address this, researchers apply corrections such as the Bonferroni method (dividing alpha by the number of comparisons), the Holm step down procedure, or the Benjamini Hochberg procedure for controlling the false discovery rate.^[1] The choice of correction method depends on the number of comparisons, the correlation structure among tests, and whether the priority is controlling the family wise error rate or the false discovery rate.

The alpha level is also intimately connected to statistical power and sample size. For a given effect size, a lower alpha requires a larger sample to maintain adequate power (the probability of correctly rejecting a false null hypothesis).^[1][2] This tradeoff means that researchers must balance the desire to minimize false positives (lower alpha) against the practical constraints of recruitment and resources.

A hypothesis test that ends in a reject or do not reject decision needs a pre specified alpha level. The conventional 0.05 is appropriate for most single comparison analyses in clinical, behavioral, and social science research. Stricter thresholds are warranted in genome wide association studies (where alpha is typically 5 times 10 to the negative 8), in other settings with very many comparisons, in confirmatory studies where a false positive would be costly, or in fields with documented replication problems. More lenient thresholds (such as 0.10) may be appropriate for exploratory or pilot studies where the goal is to identify promising leads rather than to confirm effects.

A clinical trial protocol for a new antihypertensive drug specifies two primary endpoints, reduction in systolic blood pressure and reduction in cardiovascular events, and the drug may be declared effective if either endpoint succeeds. Because success on either endpoint is enough for a claim, there are two chances for a false positive, so to maintain an overall two sided Type I error rate of 0.05 the statistical analysis plan uses a Bonferroni correction, testing each endpoint at a two sided alpha of 0.025. (If both endpoints had to succeed, as with true co primary endpoints, this adjustment would not be needed.) The cardiovascular endpoint drives the sample size: about 1,440 events give 80% power to detect a 15% relative reduction in risk (hazard ratio 0.85) at the adjusted alpha, so the trial plans to enroll about 14,400 participants, assuming 10% of them have an event during follow-up. That is far more than the roughly 450 participants needed for 90% power to detect a 5 mmHg difference in systolic blood pressure (standard deviation 15 mmHg).